Skip to main content

On/Go test to Treat offers speed, convenience and safety with home testing, telehealth prescriptions and antiviral delivery from Paxlovid within hours via its mobile app, which now also includes support for long COVID

MIAMI, October 26, 2022 /PRNewswire/ — intrivothe leading health technology company behind Walk/Go rapid COVID-19 tests and AI-powered tests mobile apptoday announced the launch of its free at-home service Test to treat program, as well as new medical support resources for those suffering from long COVID. On/Go test to Treat is the most accessible and transparent end-to-end treatment testing solution on the market, launched at a crucial time when Americans are struggling to access COVID treatments like the antiviral drug Paxlovid. As cases rise around the world and new variants of COVID-19 emerge, On/Go provides speed, convenience and safety by allowing eligible users who test positive to receive free antiviral medication without leaving home.

Intrivo Logo (PRNewsfoto/Intrivo)

“Speed ​​matters with Paxlovid,” said Dr. Roger Seheult, MD, member of the Intrivo Medical Advisory Board. “Right now we need to help more people because simply 11% of Americans with COVID-19 are prescribed antiviral treatment. On/Go test to Treat is a fast and innovative way to help people in their homes within hours. It is the future of COVID-19 treatment and a precursor to many other potential use cases.”

The solution was designed by Intrivo’s internal team of user experience experts, engineers and data scientists to be widely applicable to other types of processing in the future. To use On/Go test to treat, consumers are using the #1 rated COVID On/Go test, which is free with reimbursement from health insurance, and follow a few simple steps:

  1. Download the On/Go mobile app to iOS Where android.

  2. Follow the instructions to take the test and receive the results.

  3. If the results are positive, complete a brief eligibility form in the app, which an independent clinician reviews to determine if you are a candidate for Paxlovid treatment.

  4. If treatment is the right option, choose a pharmacy where the clinician can dispense a Paxlovid prescription.

  5. Choose free and fast delivery and the drugs arrive at your doorstep within hours.

“We now have more tools to control the spread of COVID-19 more effectively than before, but it’s not always easy for people to access them quickly, easily and affordably,” said Ron Gutman, Co-CEO of Intrivo. “With our Test-to-Treat solution, we are ensuring that eligible people who really need Paxlovid can start their antiviral prescriptions almost immediately, because we know time is running out and we have the cutting-edge technology to When someone tests positive, they may not know what to do next – from test results to getting prescriptions filled to fast delivery and lingering symptoms, we have our users’ backs and can help them control COVID-19 for good.”

About one in five people (19%) who get COVID-19 end up with long-lasting COVID-related complications, so On/Go has also launched a new service to help people manage persistent symptoms, as they have an urgent need to reduce suffering and anxiety. The On/Go long COVID solution includes an easy-to-use symptom checker and access to a COVID-19 Virtual Care Clinic, featuring live telemedicine video calls with specially trained clinicians. The harmful effects of long COVID reduce quality of life and may include fatigue, difficulty concentrating, memory problems, shortness of breath, joint and muscle pain, heart palpitations, chest pain, dizziness, menstrual changes, taste changes and smell, inability to exercise, etc. Intrivo’s long COVID support was developed with leading clinical experts across the country, including Stanford UniversityIntrivo-based researchers and Intrivo’s internal medical advisory board. These experts guide product development with the latest research and treatment options.

“We envision a world where sick people don’t have to put themselves and others at risk just to get the life-saving treatment they need,” said Reeve Benaron, co-CEO of Intrivo. “Healing people from the comfort of their own homes is the future of healthcare, and our goal is to help everyone stay safe, especially as we enter this winter when cases of COVID- 19 are traditionally on the rise.”

To experience On/Go test to Treat and long COVID virtual care, and learn more about how Intrivo is creating innovative and delicious technology to keep Americans healthier and safer, download the On/Go mobile app and visit and

About On/Go:

On/Go is a reliable self-testing platform that helps people live healthier lives by combining a quick and easy-to-use COVID-19 test with a cutting-edge AI-powered mobile app. Since its launch in 2020, On/Go has helped hundreds of millions of people with fast and accurate testing. The brand’s first antigen test, Walk/Go one, delivers results with 98.2% accuracy in 15 minutes, detects all major known variants of COVID-19, and works with or without symptoms. The smartphone-sized test pairs with the top-rated On/Go companion mobile app to make testing simple and portable. The tests are covered by insurance and can be purchased on Amazon and for home delivery. The On/Go app includes antiviral prescriptions via telemedicine, testing advice, live medical assistance, instructional videos, virtual health resources and more. On/Go is supported by intrivoThe data-driven population health platform, which enables hospitals and other organizations to understand viral trends based on test results and identify clusters of infections in real time. For more information, visit

About Intrivo:

Intrivo is a Miamibased on healthcare technology that harnesses the power of AI and user-centered design to deliver the first scalable and comprehensive test-tracing solution on the market. Intrivo’s Diagnostics as a Service (DaaS)™ is a reliable, high-quality solution that helps consumers, businesses, and organizations stay ahead of the COVID-19 curve. It combines the best Walk/Go self-testing with an AI-backed open-source platform to revolutionize the way people, organizations and communities identify viral outbreaks and make health decisions in real time.

Founded in 2020 at the onset of the global pandemic, Intrivo continues to fight on the frontlines against COVID-19, actively working to apply its team’s expertise in expanded capabilities and forging new partnerships with stakeholders across the world. sectors of the healthcare ecosystem. Intrivo’s ultimate goal is to make healthcare more accessible and affordable for consumers and businesses, enabling people to live healthier, happier and safer lives. To learn more about Intrivo’s world-class technology solutions, visit

This product has not been cleared or approved by the FDA, but has been cleared by the FDA under an Emergency Use Authorization (EUA). This product has been licensed for the detection of SARS-CoV-2 proteins only, and not for other viruses or pathogens. This product is authorized only for the duration of the declaration of the existence of circumstances justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 USC § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Contact: [email protected]



View original content to download multimedia: -providing-fast-home-delivery-of-antiviral-drugs-and-covid-long-assistance-301659353.html